


PHARMACEUTICAL 2023

Cellectar Biosciences Inc. Rank 311 of 446







Cellectar Biosciences Inc. Rank 311 of 446

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is -14%, being 57% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	20,530
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,529
Liabilities, Non-Current	553
Other Assets	642
Other Compr. Net Income	0
Other Expenses	-60
Other Liabilities	0
Other Net Income	153
Other Revenues	0
Property and Equipment	419
Research and Development	19,220
Selling, General and Administrative Expense	9,594

Output Variable	Value in 1000 USD
Assets	21,590
Liabilities	6,082
Expenses	28,754
Revenues	0
Stockholders Equity	15,508
Net Income	-28,601
Comprehensive Net Income	-28,601
Economic Capital Ratio	-14%

